Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
What are neuraminidase inhibitors and how do you quickly get the latest development progress?
What are neuraminidase inhibitors and how do you quickly get the latest development progress?
13 December 2023
Neuraminidase inhibitors are drugs that target the neuraminidase enzyme, crucial for combating influenza virus infections.
Read →
FDA Approves CARsgen's CT071 for Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia Post-Therapy Failure
Latest Hotspot
3 min read
FDA Approves CARsgen's CT071 for Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia Post-Therapy Failure
13 December 2023
FDA Grants Approval for CARsgen's Experimental Treatment CT071 for Use in Cases of Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia After Prior Therapies Fail.
Read →
What is lethal synthesis?
Knowledge Base
2 min read
What is lethal synthesis?
13 December 2023
Compounds resembling key metabolites can compete with them or disrupt their use, or get incorporated into biological macromolecules, creating faulty structures that hinder cell growth and can be lethal.
Read →
Brenig Therapeutics Reports BT-0267 LRRK2 Blocker Shows Improved Safety and Significant CSF Blood Levels at Parkinson's Symposium
Latest Hotspot
3 min read
Brenig Therapeutics Reports BT-0267 LRRK2 Blocker Shows Improved Safety and Significant CSF Blood Levels at Parkinson's Symposium
12 December 2023
Brenig Therapeutics Reveals Enhanced Safety Metrics for its LRRK2 Blocker BT-0267 Featuring Notable CSF-to-Blood Concentration at the Parkinson's Disease Symposium.
Read →
Understanding Mcl-1 Inhibitors and Methods to Keep Abreast of Their Recent Developments
Understanding Mcl-1 Inhibitors and Methods to Keep Abreast of Their Recent Developments
12 December 2023
Mcl-1 inhibitors are drugs that target the Mcl-1 protein, crucial for regulating cell survival and apoptosis.
Read →
Merck Enhances Cancer Drug Offering By Securing Deal with Abbisko for Market Launch of Advanced Stage Drug, Pimicotinib
Latest Hotspot
3 min read
Merck Enhances Cancer Drug Offering By Securing Deal with Abbisko for Market Launch of Advanced Stage Drug, Pimicotinib
12 December 2023
The prominent science and technology corporation, Merck, has declared a formal licensing contract with the Shanghai-based firm Abbisko Therapeutics Co. Ltd.
Read →
Biological Glossary | What is Sense Strand?
Bio Sequence
2 min read
Biological Glossary | What is Sense Strand?
12 December 2023
In biology, a sense strand or coding strand is the part of the double-stranded DNA that carries the translatable code, running in the 5' to 3' direction.
Read →
Ascletis has commenced a stage three clinical evaluation for their acne medication, ASC40, also known as Denifanstat
Latest Hotspot
3 min read
Ascletis has commenced a stage three clinical evaluation for their acne medication, ASC40, also known as Denifanstat
12 December 2023
Ascletis Pharma Inc. has declared the commencement of a pivotal Phase III clinical study for its fatty acid synthase inhibitor, ASC40 (Denifanstat) , aimed at addressing the therapeutic needs of individuals with moderate to severe acne vulgaris.
Read →
What are NS5A inhibitors and how do you quickly get the latest development progress?
What are NS5A inhibitors and how do you quickly get the latest development progress?
12 December 2023
NS5A inhibitors: Revolutionizing hepatitis C treatment with high efficacy and future potential.
Read →
Merus Showcases Preliminary Results for MCLA-129 at the 2023 ESMO Asia Congress
Latest Hotspot
3 min read
Merus Showcases Preliminary Results for MCLA-129 at the 2023 ESMO Asia Congress
12 December 2023
Merus N.V. has revealed fresh interim clinical findings on their candidate molecule MCLA-129.
Read →
Biological Glossary | What is Repeat_region?
Bio Sequence
2 min read
Biological Glossary | What is Repeat_region?
12 December 2023
In biology, a repeat region refers to a sequence of DNA that is repeated multiple times in the genome.
Read →
European regulators have approved UCB's ZILBRYSQ® (zilucoplan) for adult generalized Myasthenia Gravis treatment
Latest Hotspot
3 min read
European regulators have approved UCB's ZILBRYSQ® (zilucoplan) for adult generalized Myasthenia Gravis treatment
12 December 2023
UCB has received the green light from European regulators to market ZILBRYSQ[®] (zilucoplan) as a therapeutic option for generalized Myasthenia Gravis in adult patients.
Read →